Unicycive Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -211 | -151 | ||
EBITDA | -1,571 | -12,612 | -14,490 | -5,848 |
EBIT | -1,722 | -12,823 | -14,641 | -5,996 |
Net Income | -1,722 | -12,823 | -14,668 | -6,011 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -7,603 | -6,249 | -8,032 | -5,964 |
Cash | 44,185 | 37,371 | 29,198 | 42,695 |
Basic Shares | 26,917 | 23,908 | 19,897 | 18,065 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $675 | $951 |
Gross Profit | -572 | -428 | 675 | 951 |
EBITDA | -25,912 | -36,230 | -30,178 | -17,891 |
EBIT | -26,484 | -36,658 | -30,462 | -18,052 |
Net Income | -26,555 | -36,729 | -30,544 | -18,064 |
Net Change In Cash | 0 | 0 | 675 | 951 |
Free Cash Flow | -31,341 | -28,647 | -18,295 | -15,653 |
Cash | 29,198 | 26,142 | 9,701 | 455 |
Basic Shares | 15,886 | 6,698 | 2,453 | 1,505 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.06 |
2026-03-31 | -$0.53 |
2025-12-31 | -$0.82 |
2025-09-30 | -$0.33 |